Literature DB >> 7930494

Lithium addition in treatment-resistant depression.

C de Montigny1.   

Abstract

The addition of lithium to antidepressants as a strategy for the management of depressed patients not responding to a tricyclic antidepressant was derived from the observation in animals that long-term administration of tricyclic antidepressant drugs enhances the sensitivity of postsynaptic neurones. Lithium administration increases the function of 5-HT neurones and thus might lead to amelioration of the non-responding depression. There have now been a substantial number of studies of lithium augmentation in non-responding depressed patients and a positive effect is consistently reported. The combination of lithium with a variety of antidepressants has not been associated with excessive reports of serious adverse events and therefore appears to be a useful approach to patients with a poor response to antidepressants.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7930494     DOI: 10.1097/00004850-199406002-00006

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  3 in total

Review 1.  Risk of adverse events with the use of augmentation therapy for the treatment of resistant depression.

Authors:  I Schweitzer; V Tuckwell
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

2.  Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression.

Authors:  Tom Bschor; Christopher Baethge; Mazda Adli; Ute Lewitzka; Uta Eichmann; Michael Bauer
Journal:  J Psychiatry Neurosci       Date:  2003-05       Impact factor: 6.186

3.  Treatment-resistant depression: therapeutic trends, challenges, and future directions.

Authors:  Khalid Saad Al-Harbi
Journal:  Patient Prefer Adherence       Date:  2012-05-01       Impact factor: 2.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.